Overview

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Status:
Recruiting

Trial end date:
2023-09-18

Target enrollment:

Participant gender:

Summary

This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of endocrine therapy for advanced breast cancer.

Phase:

N/A

Details

Lead Sponsor:

Liaoning Tumor Hospital & Institute

Treatments:

Fulvestrant